Orchid Pharma - Enmetazobactam, First Indian NCE Gets U.S. FDA Nod: Systematix
1 month ago•Bloomberg Quint
Orchid Pharma - A Preferred Play On Import Substitution Opportunity: Systematix Initiates Coverage With A Buy
2 months ago•Bloomberg Quint
Orchid Pharma - Opening Up Multiple Growth Avenues: Systematix
4 months ago•Bloomberg Quint
Orchid Pharma Consolidated June 2023 Net Sales at Rs 182.92 crore, up 39.65% Y-o-Y
7 months ago•Moneycontrol
Orchid Pharma meets SEBI’s minimum public shareholding norms
8 months ago•The Hindu Businessline
Orchid Pharma seeks shareholder nod for Otsuka Chemicals
8 months ago•The Hindu Businessline
Orchid Pharma shares hit fresh high after signing tech transfer pact for cephalosporin intermediate
8 months ago•The Hindu Businessline